All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-CD47 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human CD47. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD47 antibody linked to 41BB and CD3ζ signaling domains. And the vector product was designed for the treatment of Pancreatic cancer,ovarian cancer,melanoma,lung cancer,liver cancer.
CAR Construction : Fig.1 Affinity determination by Surface Plasmon Resonance (SPR). The affinity of B6H12 to CD47 was detected by Fortebio detection. Zeng, D., Sun, Q., Chen, A., Fan, J., Yang, X., Xu, L., ... & Sun, Z. (2016). A fully human anti-CD47 blocking antibody with therapeutic potential for cancer. Oncotarget, 7(50), 83040. |
CAR Construction : B6H12-CD28-CD3ζ Fig.2 Cytotoxicity assay in vitro. Cytotoxicity of CD47-CAR-T cells versus T cells and Mock-CAR-T cells. Golubovskaya, V., Berahovich, R., Zhou, H., Xu, S., Harto, H., Li, L., ... & Wu, L. (2017). CD47-CAR-T cells effectively kill target cancer cells and block pancreatic tumor growth. Cancers, 9(10), 139. |
CAR Construction : B6H12-CD28-CD3ζ Fig.3 Determination of IL-2 release. CD47-CAR-T cells produce IL-2 in a CD47-dependent manner. Golubovskaya, V., Berahovich, R., Zhou, H., Xu, S., Harto, H., Li, L., ... & Wu, L. (2017). CD47-CAR-T cells effectively kill target cancer cells and block pancreatic tumor growth. Cancers, 9(10), 139. |
CAR Construction : B6H12-CD28-CD3ζ Fig.4 Determination of cytokines release. CD47-CAR-T cells secreted high levels of cytokines: IFN-gamma, IL-2 and IL-6 against BxPC3 cells in vitro Golubovskaya, V., Berahovich, R., Zhou, H., Xu, S., Harto, H., Li, L., ... & Wu, L. (2017). CD47-CAR-T cells effectively kill target cancer cells and block pancreatic tumor growth. Cancers, 9(10), 139. |
CAR Construction : B6H12-CD28-CD3ζ Fig.5 CD47-CAR-T cells significantly decreased BxPC3 tumor growth CD47-CAR-T cells significantly decrease BxPC3 pancreatic cancer xenograft tumor growth. Golubovskaya, V., Berahovich, R., Zhou, H., Xu, S., Harto, H., Li, L., ... & Wu, L. (2017). CD47-CAR-T cells effectively kill target cancer cells and block pancreatic tumor growth. Cancers, 9(10), 139. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CD47 (6BH12) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-ZP175). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION